Targeting IL-10 Family Cytokines for the Treatment of Human Diseases
- 1Department of Comparative Biology and Safety Sciences, Amgen, South San Francisco, California 94080
- 2Department of Biomarker Development, Genentech, South San Francisco, California 94080
- 3Department of Inflammation and Oncology, Amgen, South San Francisco, California 94080
- 4Department of Cancer Immunology, Genentech, South San Francisco, California 94080
- Correspondence: wouyang{at}amgen.com; saschar{at}gene.com
Abstract
Members of the interleukin (IL)-10 family of cytokines play important roles in regulating immune responses during host defense but also in autoimmune disorders, inflammatory diseases, and cancer. Although IL-10 itself primarily acts on leukocytes and has potent immunosuppressive functions, other family members preferentially target nonimmune compartments, such as tissue epithelial cells, where they elicit innate defense mechanisms to control viral, bacterial, and fungal infections, protect tissue integrity, and promote tissue repair and regeneration. As cytokines are prime drug targets, IL-10 family cytokines provide great opportunities for the treatment of autoimmune diseases, tissue damage, and cancer. Yet no therapy in this space has been approved to date. Here, we summarize the diverse biology of the IL-10 family as it relates to human disease and review past and current strategies and challenges to target IL-10 family cytokines for clinical use.
